TABLE I.

Patient, Tumor, and Treatment Characteristics

	N (%)				N (%)
Characteristics	Overall (N = 66)	EBRT (N = 45)	CCRT (N = 21)	P-Value	WD/MD Histology (N = 32)	PD histology (N = 34)	P-Value
Median follow-up (months)	24.5	30.0	21.9	0.067	35.3	23.0	0.335
Age
<45 years	5 (7.6%)	4 (8.9%)	1 (4.8%)		3 (9.4%)	2 (5.9%)
≥45 years	61 (92.4%)	41 (91.1%)	20 (95.2%)	0.555	29 (90.6%)	32 (94.1%)	0.592
Gender
Male	34 (51.5%)	24 (53.3%)	10 (47.6%)		18 (56.3%)	16 (47.1%)
Female	32 (48.5%)	21 (46.7%)	11 (52.4%)	0.665	14 (43.8%)	18 (52.9%)	0.455
Tumor stage
T1	0 (0%)	0 (0%)	0 (0%)		0 (0%)	0 (0%)
T2	5 (7.6%)	3 (6.7%)	2 (9.5%)		3 (9.4%)	2 (5.9%)
T3	4 (6.1%)	4 (8.9%)	0 (0%)		1 (3.1%)	3 (8.8%)
T4	57 (86.4%)	38 (84.4%)	19 (90.5%)	0.353	28 (87.5%)	29 (85.3%)	0.560
Regional node stage
N0	11 (16.7%)	8 (17.8%)	3 (14.3%)		5 (15.6%)	6 (17.6%)
N1	55 (83.0%)	37 (82.2%)	18 (85.7%)	0.723	27 (84.4%)	28 (82.4)	0.826
Distant metastasis
No	34 (51.5%)	21 (46.7%)	13 (61.9%)		15 (46.9%)	19 (55.9%)
Yes	32 (48.5%)	24 (53.3%)	8 (38.1%)	0.249	17 (53.1%)	15 (44.1%)	0.464
Histology
WD/MD	32 (48.5%)	26 (57.8%)	6 (28.6%)		—	—
PD	34 (51.5%)	19 (42.2%)	15 (71.4%)	0.027	—	—
Concurrent chemotherapy
EBRT	45 (68.2%)	—	—		26 (81.3%)	19 (55.9%)
CCRT	21 (32.3%)	—	—		6 (18.8%)	15 (44.1%)	0.027
Radiation technique
EBRT	15 (22.7%)	12 (26.7%)	3 (14.3%)	0.264	7 (21.9%)	8 (23.5%)	0.873
IMRT	51 (77.3%)		33 (73.3%)		25 (78.1%)	26 (76.5%)

EBRT, external beam radiation therapy; CCRT, concurrent chemoradiation therapy; WD/MD histology, well-differentiated/moderately differentiated histology; PD histology, poorly differentiated histology; IMRT, intensity-modulated radiation therapy.